Eneko Villanueva

Eneko Villanueva

Auto-generated profile, based on publicly available information

Eneko Villanueva

Cambridge Centre for Proteomics, Department of Biochemistry, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2019 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
RQRayner M. L. Queiroz
Rayner M. L. Queiroz
TSTom Smith
Tom Smith
EVEneko Villanueva
Eneko Villanueva
MMMaria Marti-Solano
Maria Marti-Solano
MMMie Monti
Mie Monti
KLKathryn Lilley
Kathryn Lilley

30 November 2023 in Nature Methods
Verified
Journal Article
Open access
PDF file
EVEneko Villanueva
Eneko Villanueva
TSTom Smith
Tom Smith
MPMariavittoria Pizzinga
Mariavittoria Pizzinga
MEMohamed Elzek
Mohamed Elzek
RQRayner M. L. Queiroz
Rayner M. L. Queiroz
KLKathryn Lilley
Kathryn Lilley
Although the subcellular dynamics of RNA and proteins are key determinants of cell homeostasis, their characterization is still challenging. Here we present an integrative framework to simultaneously interrogate the dynamics of the transcriptome and proteome at subcellular resolution by combining two methods: localization of RNA (LoRNA) and a streamlined density-based localization of proteins by isotope tagging (dLOPIT) to map RNA and protein to organelles (nucleus, endoplasmic reticulum and mitochondria) and membraneless compartments (cytosol, nucleolus and cytosolic granules). Interrogating all RNA subcellular locations at once enables system-wide quantification of the proportional distribution of RNA. We obtain a cell-wide overview of localization dynamics for 31,839 transcripts and 5,314 proteins during the unfolded protein response, revealing that endoplasmic reticulum-localized transcripts are more efficiently recruited to cytosolic granules than cytosolic RNAs, and that the translation initiation factor eIF3d is key to sustaining cytoskeletal function. Overall, we provide the most comprehensive overview so far of RNA and protein subcellular localization dynamics.

10 July 2020 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
EVEneko Villanueva
Eneko Villanueva
TSTom Smith
Tom Smith
RQRayner M. L. Queiroz
Rayner M. L. Queiroz
MMMie Monti
Mie Monti
MPMariavittoria Pizzinga
Mariavittoria Pizzinga
KLKathryn Lilley
Kathryn Lilley

10 February 2021 in Frontiers in Microbiology
Verified
Journal Article
Open access
PDF file
JGJudit Giménez-Roig
Judit Giménez-Roig
ENEstela Núñez-Manchón
Estela Núñez-Manchón
RARamon Alemany
Ramon Alemany
EVEneko Villanueva
Eneko Villanueva
Cristina FillatCristina Fillat
Cristina Fillat
Vaccination is the most effective method to date to prevent viral diseases. It intends to mimic a naturally occurring infection while avoiding the disease, exposing our bodies to viral antigens to trigger an immune response that will protect us from future infections. Among different strategies for vaccine development, recombinant vaccines are one of the most efficient ones. Recombinant vaccines use safe viral vectors as vehicles and incorporate a transgenic antigen of the pathogen against which we intend to generate an immune response. These vaccines can be based on replication-deficient viruses or replication-competent viruses. While the most effective strategy involves replication-competent viruses, they must be attenuated to prevent any health hazard while guaranteeing a strong humoral and cellular immune response. Several attenuation strategies for adenoviral-based vaccine development have been contemplated over time. In this paper, we will review them and discuss novel approaches based on the principle that protein synthesis from individual genes can be modulated by codon usage bias manipulation. We will summarize vaccine approaches that consider recoding of viral proteins to produce adenoviral attenuation and recoding of the transgene antigens for both viral attenuation and efficient viral epitope expression.

26 March 2024 in Molecular Systems Biology
Verified
Journal Article
Open access
MMMie Monti
Mie Monti
RHReyme Herman
Reyme Herman
LMLeonardo Mancini
Leonardo Mancini
CCCharlotte Capitanchik
Charlotte Capitanchik
KDKaren Davey
Karen Davey
EVEneko Villanueva
Eneko Villanueva
Characterising RNA–protein interaction dynamics is fundamental to understand how bacteria respond to their environment. In this study, we have analysed the dynamics of 91% of the Escherichia coli expressed proteome and the RNA-interaction properties of 271 RNA-binding proteins (RBPs) at different growth phases. We find that 68% of RBPs differentially bind RNA across growth phases and characterise 17 previously unannotated proteins as bacterial RBPs including YfiF, a ncRNA-binding protein. While these new RBPs are mostly present in Proteobacteria, two of them are orthologs of human mitochondrial proteins associated with rare metabolic disorders. Moreover, we reveal novel RBP functions for proteins such as the chaperone HtpG, a new stationary phase tRNA-binding protein. For the first time, the dynamics of the bacterial RBPome have been interrogated, showcasing how this approach can reveal the function of uncharacterised proteins and identify critical RNA–protein interactions for cell growth which could inform new antimicrobial therapies.

9 April 2021 in NAR Cancer
Verified
Journal Article
Open access
PDF file
ENEstela Núñez-Manchón
Estela Núñez-Manchón
MFMartí Farrera-Sal
Martí Farrera-Sal
MOMarc Otero-Mateo
Marc Otero-Mateo
GCGiancarlo Castellano
Giancarlo Castellano
RMRafael Moreno
Rafael Moreno
Cristina FillatCristina Fillat
Cristina Fillat
Arming oncolytic adenoviruses with therapeutic transgenes is a well-established strategy for multimodal tumour attack. However, this strategy sometimes leads to unexpected attenuated viral replication and a loss of oncolytic effects, preventing these viruses from reaching the clinic. Previous work has shown that altering codon usage in viral genes can hamper viral fitness. Here, we have analysed how transgene codon usage impacts viral replication and oncolytic activity. We observe that, although transgenes with optimized codons show high expression levels at the first round of infection, they impair viral fitness and are therefore not expressed in a sustained manner. Conversely, transgenes encoded by suboptimal codons do not compromise viral replication and are thus stably expressed over time, allowing a greater oncolytic activity both in vitro and in vivo. Altogether, our work shows that fine-tuning codon usage leads to a concerted optimization of transgene expression and viral replication paving the way for the rational design of more efficacious oncolytic therapies.